Browsing Tag
Bayer AG
4 posts
Bayer (ETR: BAYN) commits over C$45m to new Canadian canola innovation centre in Winnipeg
Bayer is investing over CAD 45M in a new canola innovation centre in Winnipeg. Find out what it means for trait development, seed strategy, and R&D scale.
FDA approves Bayer’s Lynkuet, a first-in-class dual NK-1/NK-3 antagonist for menopausal hot flashes
Find out how Bayer’s Lynkuet is changing menopause care with the first dual-neurokinin receptor antagonist approved by the FDA for hot flashes!
MHRA approves Bayer’s Lynkuet as first non-hormonal treatment for menopause hot flushes
Bayer’s Lynkuet becomes the world’s first approved non-hormonal menopause pill. Find out what MHRA’s decision means for women’s health today.
BlueRock Therapeutics and Bayer dose first patient in clinical trial of iPSC-derived OpCT-001 therapy for vision loss
BlueRock Therapeutics and Bayer AG have dosed the first patient in their Phase 1/2a CLARICO trial of OpCT-001, a novel iPSC-derived therapy targeting primary photoreceptor diseases.